While the TP53 signature has demonstrated strong predictive value for pCR, other multi-gene expression assays, such as the 21-gene recurrence score (RS), the 70-gene signature and PAM50, have also been validated to predict pCR in breast cancer patients undergoing NAC. Here, TP53 is linked to breast cancer.